Alembic Pharmaceuticals on Tuesday said its joint venture, Aleor Dermaceuticals has received approval from the US health regulator for its generic version of Temovate topical solution which is used to treat a variety of skin conditions. The approval by the US Food and Drug Administration (USFDA) is for Clobetasol Propionate topical solution USP, 0.05 per cent, which is therapeutically equivalent to the reference listed drug product Temovate Topical Solution, 0.05 per cent, of Fougera Pharmaceuticals Inc, the company said in a regulatory filing.
